January 7, 2026 — Leads & Copy — Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that the Compensation Committee of its Board of Directors approved inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees on January 6, 2026.
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, adopted on April 27, 2017, which provides for equity awards to new Puma employees.
The restricted stock unit awards vest over three years, with one-third of the shares vesting on the first anniversary of the award’s vesting commencement date, January 1, 2026, and one-sixth vesting on each six-month anniversary thereafter, subject to continued service.
The awards were granted as an inducement material to the new employees entering employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011.
Neratinib, oral was approved by the FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets.
In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered an exclusive license agreement for developing and commercializing alisertib, an orally administered inhibitor of aurora kinase A. Puma intends to initially focus alisertib’s development on small cell lung cancer and breast cancer.
In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib with endocrine therapy for patients with HER2-negative, HR-positive metastatic breast cancer.
Source: Puma Biotechnology
